Recently, the 42nd China Pharmaceutical Industry Information Conference and the 2025 Beijing Changping Forum on Life Sciences opened in Beijing. With the theme of “Ignite Life for Future,” the event was attended by senior officials from the Ministry of Industry and Information Technology, the National Medical Products Administration (NMPA), and the Beijing Municipal Government, who delivered keynote speeches. The conference brought together leading experts and representatives from government, industry, academia, research institutions, and healthcare, building a collaborative innovation cluster to drive high-quality development of China’s pharmaceutical industry and shape a globally influential industrial landmark.
The China Pharmaceutical Industry Information Conference is a flagship annual event in the pharmaceutical sector. First held in 1959, it has now been successfully organized 42 times. The conference has not only witnessed the development journey of China’s pharmaceutical industry but also documented the advancements and achievements in pharmaceutical science and technology in the new era. It is widely regarded as a “barometer of the pharmaceutical industry.”
During the conference, a dedicated exhibition showcased innovations in the biopharmaceutical field, including 20 innovative drugs and 15 innovative medical devices. Among them were 7 innovative drugs and 10 innovative medical devices from Beijing. AccuMedical’s Lattice NEXT Flow Diverter—featuring a non-tapered, headless design—was prominently presented as a representative innovative medical device. The showcased innovations were selected based on criteria such as clinical value and technological advancement. Enterprises across the industry submitted their achievements through an open call, with qualifying innovations exhibited in a comprehensive format that reflects the evolving innovation ecosystem during the 14th Five-Year Plan period.
AccuMedical’s Lattice NEXT features a groundbreaking “non-extended” headless guidewire design and an optimized stent delivery system. These innovations significantly enhance device navigability and deployment in the treatment of intracranial aneurysms, particularly in tortuous vascular anatomies. The device’s suite of cutting-edge technologies reduces surgical complexity for clinicians, shortens procedure times, and improves patient outcomes and safety—ushering in a new “automatic gear” era in aneurysm treatment and truly addressing clinical needs.
Since its founding, AccuMedical has made technological innovation its core competitive advantage. To date, the company has obtained NMPA approvals for nine products, including Lattice and Lattice NEXT, and filed 132 patent applications—73 of which have been granted. AccuMedical was recognized as a National High-Tech Enterprise in 2023 and as a National-level “Little Giant” Enterprise in 2024. Looking ahead, AccuMedical will continue advancing innovation in the field of neurointervention and contribute Chinese strength to global health.
